Dupilumab Shown to Reduce COPD Exacerbations Substantially in New Phase 3 Data
This data from the NOTUS trial is set to be submitted to the FDA alongside the phase 3 BOREAS trial data later in the year.
Source: hcplive.com
Page 45 - Breakthrough Therapy News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Breakthrough Therapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Breakthrough Therapy Today - Breaking & Trending Today
NRx Pharmaceuticals to Present at Noble Capital Markets' 19th Annual Emerging Growth Investor Conference
RADNOR, Pa., Nov. 27, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, today announced that Dr. Jonathan Javitt, Founder and Chief Scientist of NRx...
Source: marketscreener.com
Pegozafermin Shows Sustained Benefit for NASH in Phase 2b Extension Study
Results from the 24-week extension period of the phase 2b ENLIVEN trial showed sustained improvements in liver fat, fibrosis, and inflammation among those treated with 30 mg weekly and 44 mg biweekly pegozafermin.
Source: hcplive.com
89bio Announces New Positive Long-Term Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH)
—Data at week 48 demonstrated that treatment with pegozafermin led to sustained statistically significant improvements across liver fat and non-invasive tests of liver injury/inflammation and...
Source: marketscreener.com
Abeona Therapeutics Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics ...
- PDUFA target action date is May 25, 2024 -
Source: eagletribune.com